Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rejuvenated Roche’s Pipeline Promises Innovation, Profitability

Executive Summary

Two years after a painful restructuring to offset product setbacks and downward pressure on drug prices and three years after buying California-based biotech Genentech, Roche of Switzerland says it is fighting fit again, armed with a fully-laden pipeline and poised for new launches that increasingly focus on personalized health care.

Advertisement

Related Content

An NME Surge After The Patent Cliff? Reinvention Of R&D Starts Paying Off In 2013 New Product Candidates
An NME Surge After The Patent Cliff? Reinvention Of R&D Starts Paying Off In 2013 New Product Candidates
Investors See Pharma Promise In 2013, Look Past Patent Cliff
Roche Oncology Turns In A Third Quarter To Rival The Good Old Days
Roche Third-Quarter Pipeline Adjustments Include Advancements, Delays
AZ Taps Outsider Soriot As CEO, While Roche Anoints 25-Year Veteran O'Day To Head Pharma Division
Is Diagnostics the New Biotech...and Will Pharma Embrace It?
Roche Wins Genentech After Months-Long Battle

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054720

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel